Back to News & Resources

Understanding HTA Submissions: NICE, SMC and Beyond

Every pharmaceutical and biotech company looking to bring a product to market in the UK or Europe must confront one hurdle: the HTA submission. You may have brilliant clinical data, regulatory green lights and a manufacturing setup ready to go, but without the green light from health technology assessment bodies like NICE or SMC, you’re not getting market access.

An HTA submission isn’t just paperwork. It’s a statement that your product has a place in the national healthcare system. Miss the mark here and you won’t just lose months. You could lose the market altogether.

This article breaks down what’s involved in an HTA submission, where companies go wrong and how you can avoid preventable failure.

HTA Submission Basics: What’s Being Evaluated?

Before we move further, let’s get clear on what HTA submissions assess. These bodies don’t just review whether a drug or therapy works. They evaluate whether it’s worth the cost to the health system. Every claim must stand up to clinical, economic and operational scrutiny, with regulators expecting evidence that your product will deliver measurable value in a real-world healthcare setting.

What Do NICE and SMC Evaluate?

Both the National Institute for Health and Care Excellence (NICE) in England and the Scottish Medicines Consortium (SMC) assess five core components:

  • Clinical effectiveness vs standard of care
  • Cost-effectiveness through economic modelling
  • Patient access considerations
  • Budget impact
  • Broader health outcomes

Each body has different timelines, formats and processes. But they all demand solid evidence that your product solves a defined problem at a justifiable cost.

Who Needs to Submit?

If you’re launching a product in the UK, you’re in NICE or SMC’s queue. Selling in Scotland without SMC sign-off means working without NHS support. And beyond the UK, countries like France (HAS), Germany (G-BA) and Canada (CADTH) operate under similar HTA frameworks.

NICE vs. SMC: Know the Playing Field

There are differences between these two systems. Understanding what separates them can mean the difference between approval and a lengthy, expensive appeal. Each body applies its own evaluation lens, timelines and documentation standards. What satisfies one may fall short with the other.

NICE: England and Wales

NICE reviews typically take 6–9 months and follow the Single Technology Appraisal (STA) process. Your data must be watertight, your cost-effectiveness model tight and your comparators directly relevant to UK practice. Here’s what you need to know if you’re preparing a submission for NICE.

  • Focuses heavily on incremental cost-effectiveness ratios (ICERs)
  • Open consultation and stakeholder involvement
  • Publishes detailed public reports

SMC: Scotland

SMC’s process is faster, around 18 weeks, but that doesn’t mean easier. If you’re targeting market access in Scotland, the SMC submission process comes with its own demands. It moves quickly but expects clarity and precision right from the start:

  • Uses a New Product Assessment Form (NPAF)
  • No formal consultation with patients or stakeholders
  • Final decision is binding and issued quickly

HTA submission timelines and review depth vary, but both demand preparation long before your launch window.

Where Most HTA Submissions Fail and Why

Pharma companies tend to fall into the same traps. Not because they’re unprepared, but because they underestimate how HTA committees think. These submissions aren’t just technical. They’re strategic and missing the mark on even one expected detail can shut the door on reimbursement.

The Cost-Effectiveness Model Isn’t Localised

You used data from global trials and models that work for FDA review. That’s not enough. NICE and SMC want local health economic data, with UK pricing, NHS comparators and expected treatment patterns.

The Comparator Is Irrelevant

If your HTA submission fails to address the treatments commonly used in the NHS, reviewers will flag it. It’s not about the best alternative. It’s about the actual standard of care in the market you’re targeting.

You Forgot the Patient Impact

Patient-reported outcomes, adherence data and administration considerations are not optional additions. They are central to how HTA committees assess overall value. Overlooking these elements significantly weakens the credibility and completeness of your submission.

GMP and GDP: The Overlooked Dealbreakers

An often-overlooked risk in the submission process is the impact of GMP and GDP documentation. While regulatory approval may secure market authorisation, deficiencies in quality assurance or distribution practices can trigger serious concerns during the HTA submission review, potentially delaying or preventing reimbursement approval.

Manufacturing Compliance Matters

HTA reviewers often request evidence of consistent quality, supply readiness and scale-up feasibility. If your GMP compliance support is lacking, your therapy’s reliability will be questioned.

  • Batch production records
  • Quality assurance audits
  • Risk assessments for contamination or shortages

GDP and Distribution Control

Distribution affects cost, accessibility and availability. Any weak link in your GDP audit support, from storage temperature concerns to unclear chain of custody, can get flagged in the value assessment. HTA bodies don’t just want a good product. They want a dependable supply model.

Your HTA Submission Checklist

Here’s what must be buttoned up before submitting to NICE, SMC or any other HTA body. Each component on this checklist plays a direct role in how your product is assessed for value, viability and funding potential.

  • Health economic model with UK-specific inputs
  • Clear comparison with the NHS standard of care
  • Evidence of GMP-certified production
  • GDP-compliant distribution plans
  • Submission-ready NPAF (SMC) or STA documentation (NICE)
  • Quality-adjusted life year (QALY) impact
  • Budget impact estimate across NHS regions
  • Evidence of clinical utility in UK populations
  • Inclusion of patient-reported outcomes
  • Adverse event monitoring plan

Anything missing? You’re likely to get follow-up questions that delay approval.

It’s Not One Submission Fits All

Each country has its own requirements. What passes in the UK won’t cut it in Germany and vice versa. That’s why multinationals need region-specific planning.

Examples Across Borders

Here’s how different regions approach the process:

  • Germany’s G-BA focuses heavily on added benefits compared to existing therapies and mandates a dossier immediately after EMA approval.
  • France’s HAS uses a two-part evaluation: medical benefit and improvement in medical benefit (SMR and ASMR).
  • Canada’s CADTH reviews both clinical and economic evidence, but provinces may apply individual reimbursement decisions.

Bottom line: Regulatory success does not equal HTA submission success. Separate teams, separate timelines.

A Note on Timing: Get QA Involved Early

Most companies wait too long to involve quality assurance in their HTA submission process. This mistake costs time, increases risk and can lead to red flags during the assessment.

When Should QA Step In?

Immediately after Phase II data. That’s the point where your manufacturing narrative must begin aligning with your value narrative. Having this ready can prevent a last-minute panic before submission. Your QA team should help:

  • Audit all manufacturing processes in use
  • Review change control logs for stability
  • Document quality issues and corrective actions

Four Facts No One Tells You About HTA Submissions

These aren’t just statistics. They’re caution signs. If you miss them, you’ll be stuck in an endless resubmission loop.

  1. NICE can reject products that meet efficacy benchmarks if cost-effectiveness models don’t align with UK-specific pricing references.
  2. The average delay between EMA approval and first NHS reimbursement is 14–18 months, much of which comes from back-and-forth on HTA submissions.
  3. More than 70% of rejections from SMC are due to failure to demonstrate a clear added benefit over comparators, not efficacy.
  4. GDP violations in post-approval audits have led to HTA re-evaluations of previously approved products, especially in orphan and speciality drug categories.

Ready to Submit? Check These Final Red Flags

Before you push the button on your HTA submission, take five minutes and ask:

  • Is our ICER realistic based on NHS reference pricing?
  • Have we modelled adherence impact for real-world conditions?
  • Did our cost model include GDP-related variables (storage, wastage)?
  • Have we pre-cleared any unusual safety data with regulators?
  • Are all our data sources reproducible and transparent?

If you’re second-guessing even one of those answers, it’s not time to submit yet.

Your Next Step: Get Your Submission Reviewed by HTA Experts Who Know the System

Securing approval often depends not just on the strength of your data but on how effectively your submission communicates that value. This is where Inglasia provides the strategic support needed to align every element of your HTA submission with regulatory expectations.

We’ve supported dozens of companies with HTA submissions across NICE, SMC, HAS, G-BA, CADTH and more. Our strength lies in knowing what regulators are looking for and making sure your team doesn’t miss what they didn’t think to check. We help pharma and biotech companies:

  • Validate and polish their economic models
  • Prepare submission-ready GMP and GDP documentation
  • Structure evidence for market-specific requirements
  • Anticipate reviewer objections before they’re raised

Ready to Submit with Confidence? Let’s Make Sure It Lands Right

If your HTA submission isn’t bulletproof, it’s not ready. At Inglasia, we guide pharmaceutical and biotech companies through every step – refining your value story, validating your data and ensuring your documentation meets what NICE, SMC and global HTA bodies expect. 

Our experts don’t just review. We pinpoint exactly what needs to be fixed before your submission hits their desks. Contact us now and we’ll show you exactly where you stand and what to do next.